-DOCSTART- -X- O
Chronic -X- _ B-Patient
hepatitis -X- _ I-Patient
B -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
HBV -X- _ I-Patient
) -X- _ I-Patient
infection -X- _ I-Patient
represents -X- _ O
a -X- _ O
worldwide -X- _ O
public -X- _ O
health -X- _ O
concern -X- _ O
with -X- _ O
approximately -X- _ O
250 -X- _ O
million -X- _ O
people -X- _ O
chronically -X- _ O
infected -X- _ O
and -X- _ O
at -X- _ O
risk -X- _ O
of -X- _ O
developing -X- _ O
liver -X- _ O
cirrhosis -X- _ O
and -X- _ O
hepatocellular -X- _ O
carcinoma. -X- _ O
Nucleos -X- _ O
( -X- _ O
t -X- _ O
) -X- _ O
ide -X- _ O
analogues -X- _ O
( -X- _ O
NUC -X- _ O
) -X- _ O
are -X- _ O
the -X- _ O
most -X- _ O
widely -X- _ O
used -X- _ O
therapies -X- _ O
for -X- _ O
HBV -X- _ O
infection -X- _ O
, -X- _ O
but -X- _ O
they -X- _ O
often -X- _ O
require -X- _ O
long-lasting -X- _ O
administration -X- _ O
to -X- _ O
avoid -X- _ O
the -X- _ O
risk -X- _ O
of -X- _ O
HBV -X- _ O
reactivation -X- _ O
at -X- _ O
withdrawal. -X- _ O
Therefore -X- _ O
, -X- _ O
there -X- _ O
is -X- _ O
an -X- _ O
urgent -X- _ O
need -X- _ O
to -X- _ O
develop -X- _ O
novel -X- _ O
treatments -X- _ O
to -X- _ O
shorten -X- _ O
the -X- _ O
duration -X- _ O
of -X- _ O
NUC -X- _ O
therapy -X- _ O
by -X- _ O
accelerating -X- _ O
virus -X- _ O
control -X- _ O
, -X- _ O
and -X- _ O
to -X- _ O
complement -X- _ O
the -X- _ O
effect -X- _ O
of -X- _ O
available -X- _ O
anti-viral -X- _ O
therapies. -X- _ O
In -X- _ O
chronic -X- _ O
HBV -X- _ O
infection -X- _ O
, -X- _ O
virus-specific -X- _ O
T -X- _ O
cells -X- _ O
are -X- _ O
functionally -X- _ O
defective -X- _ O
, -X- _ O
and -X- _ O
this -X- _ O
exhaustion -X- _ O
state -X- _ O
is -X- _ O
a -X- _ O
key -X- _ O
determinant -X- _ O
of -X- _ O
virus -X- _ O
persistence. -X- _ O
Reconstitution -X- _ O
of -X- _ O
an -X- _ O
efficient -X- _ O
anti-viral -X- _ O
T -X- _ O
cell -X- _ O
response -X- _ O
may -X- _ O
thus -X- _ O
represent -X- _ O
a -X- _ O
rational -X- _ O
strategy -X- _ O
to -X- _ O
treat -X- _ O
chronic -X- _ O
HBV -X- _ O
patients. -X- _ O
In -X- _ O
this -X- _ O
perspective -X- _ O
, -X- _ O
the -X- _ O
enhancement -X- _ O
of -X- _ O
adaptive -X- _ O
immune -X- _ O
responses -X- _ O
by -X- _ O
a -X- _ O
checkpoint -X- _ B-Intervention
inhibitor -X- _ I-Intervention
blockade -X- _ I-Intervention
, -X- _ I-Intervention
specific -X- _ I-Intervention
T -X- _ I-Intervention
cell -X- _ I-Intervention
vaccines -X- _ I-Intervention
, -X- _ I-Intervention
lymphocyte -X- _ I-Intervention
metabolism -X- _ I-Intervention
targeting -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
autologous -X- _ I-Intervention
T -X- _ I-Intervention
cell -X- _ I-Intervention
engineering -X- _ I-Intervention
, -X- _ I-Intervention
including -X- _ I-Intervention
chimeric -X- _ I-Intervention
antigen -X- _ I-Intervention
receptor -X- _ I-Intervention
( -X- _ I-Intervention
CAR -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
TCR-redirected -X- _ I-Intervention
T -X- _ I-Intervention
cells -X- _ I-Intervention
, -X- _ O
constitutes -X- _ B-Outcome
a -X- _ I-Outcome
promising -X- _ I-Outcome
immune -X- _ I-Outcome
modulatory -X- _ I-Outcome
approach -X- _ I-Outcome
for -X- _ I-Outcome
a -X- _ I-Outcome
therapeutic -X- _ I-Outcome
restoration -X- _ I-Outcome
of -X- _ I-Outcome
protective -X- _ I-Outcome
immunity. -X- _ I-Outcome
The -X- _ O
advances -X- _ O
of -X- _ O
the -X- _ O
emerging -X- _ O
immune-based -X- _ O
therapies -X- _ O
in -X- _ O
the -X- _ O
setting -X- _ O
of -X- _ O
the -X- _ O
HBV -X- _ O
research -X- _ O
field -X- _ O
will -X- _ O
be -X- _ O
outlined -X- _ O
. -X- _ O

